Medivir announces that Simeprevir data will be presented at the upcoming AASLD meeting

        Print
| Source: Medivir AB
Stockholm, Sweden — Medivir AB (OMX: MVIR) announced that data will be presented
on the investigational protease inhibitor simeprevir for the treatment of
genotype 1 chronic hepatitis C in adult patients with compensated liver disease
at the upcoming Annual Meeting of the American Association for the Study of
Liver Diseases (AASLD), which will take place November 1 to 5 in Washington,
D.C.

The data to be presented at the 2013 AASLD Annual Meeting include:

Poster Presentations: HCV Therapeutics: New Agents, Poster Hall, November 3,
8:00 a.m. - 5:30 p.m. (EST):

  · Simeprevir (TMC435) with peg-interferon α-2a/ribavirin for treatment of
chronic HCV genotype 1 infection in patients who relapsed after previous
interferon-based therapy: Efficacy and safety in patient sub-populations in the
PROMISE Phase III trial
    · Lead Author: Xavier Forns, Hospital Clinic, Barcelona, Spain

  · Adding simeprevir to peginterferon/ribavirin for HCV shortens time with
patient-reported symptoms and impairment in quality of life: Results from the
simeprevir Phase III QUEST 1, QUEST 2, and PROMISE studies
    · Lead Author: Jane A. Scott, Janssen

  · Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic
HCV genotype 1 infection in treatment-naïve patients: Efficacy in difficult-to
-treat patient sub-populations in the QUEST-1 and 2 Phase III trials
    · Lead Author: Ira M. Jacobson, Weill Cornell Medical College, New York, USA

  · Resistance analyses of HCV isolates from patients treated with simeprevir in
Phase 2b/3 studies
    · Lead Author: Oliver Lenz, Janssen

Full session details and data presentation listings for the 2013 AASLD Annual
Meeting can be found at http://www.aasld.org/livermeeting.

For more information please contact:
Rein Piir, EVP Corporate Affairs & IR
Mobile: +46 708 537 292.

About simeprevir
Simeprevir is an investigational NS3/4A protease inhibitor jointly developed by
Janssen R&D Ireland and Medivir AB for the treatment of genotype 1 chronic
hepatitis C in adult patients with compensated liver disease, including all
stages of liver fibrosis. Simeprevir works by blocking the protease enzyme that
enables the hepatitis C virus to replicate in host cells.

For additional information about simeprevir clinical trials, please visit
www.clinicaltrials.gov.

About Medivir
Medivir is an emerging research-based pharmaceutical company focused on
infectious diseases. Medivir has world class expertise in polymerase and
protease drug targets and drug development which has resulted in a strong
infectious disease R&D portfolio. The Company’s key pipeline asset is
simeprevir, a novel protease inhibitor for the treatment of hepatitis C that is
being developed in collaboration with Janssen R&D Ireland. Medivir has also a
broad product portfolio with prescription pharmaceuticals in the Nordics.

For more information about Medivir AB, please visit the Company’s website:
www.medivir.com